KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Travere Therapeutics (TVTX) over the last 11 years, with Q3 2025 value amounting to $1.5 million.

  • Travere Therapeutics' Receivables - Other fell 4000.0% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 4000.0%. This contributed to the annual value of $2.3 million for FY2024, which is 5000.0% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Receivables - Other is $1.5 million, which was down 4000.0% from $1.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Receivables - Other high stood at $4.6 million for Q4 2023, and its period low was $900000.0 during Q4 2021.
  • Moreover, its 5-year median value for Receivables - Other was $2.3 million (2024), whereas its average is $2.5 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first skyrocketed by 14210.53% in 2023, then tumbled by 5000.0% in 2024.
  • Over the past 5 years, Travere Therapeutics' Receivables - Other (Quarter) stood at $900000.0 in 2021, then surged by 111.11% to $1.9 million in 2022, then soared by 142.11% to $4.6 million in 2023, then crashed by 50.0% to $2.3 million in 2024, then crashed by 34.78% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $2.1 million during Q1 2025.